Yasser Fouad, Reda Elwakil, Faisal M. Sanai, O. S. Ojo, Sameer Al Awadhi, Ponsiano Ocama, Nadia A Abdelkader, Said A. Al-Busafi, Yaw Asante Awuku, Samy A. Zaki, Maheeba Abdulla, Masolwa Ng'wanasayi, Ebada Said, Munira Y. Altarrah, Mortada El‐Shabrawi, Reidwan Ally, Mohamed Tahiri, Shamardan Ezzeldin S. Bazeed, Yousef Ajlouni, Ahmed Aly Gomaa, A.A. Hamed, Hailemichael Desalegn, Moutaz Derbala, Enas Kamal, Abdulmunem A. Abdo, M. Sabbah, Mai Mehrez, Amal Shahat, D A Ndububa, Eman Fares, Nawel Afredj, Alaa M Mostafa, Almoutaz Hashim, Rasha Eletreby, Manar Sayed Farhat, Yahya Ghanem, A. Salama, Nabil Debzi, Doaa Abdeltawab, Yousry Esam-Eldin Abo-Amer, Shaymaa Nafady, Violet Kayamba, Mariam G Zaghloul, Shereen Abdel Alem, Doaa Elwazzan, Omar Elwakil, Abdulla Al Hassani, Nawal Alkhalidi, Mohamed Sharaf‐Eldin, Necati Örmecİ, Mohammed Eslam
Over the past few decades, the profile of liver diseases in Africa and the Middle East has undergone significant changes. The incidence of metabolic dysfunction-associated fatty liver disease (MAFLD) has risen to alarming levels. Despite the seriousness of the situation, there is a scarcity of local or regional guidelines established to address it. This document presents the clinical practice guidelines from the African Middle East Association of Gastroenterology (AMAGE) related to the screening, diagnosis, and management of MAFLD. It addresses multiple aspects of managing this condition while taking into account local circumstances and the healthcare system's management requirements. These guidelines are intended for routine clinical use, with a specific focus on particular groups when needed.